A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats

Journal of Medicinal Chemistry

Volumn 48, Issue 22, 2005, Pages 6772-6775

  Hummel, Conrad W ^b   Geiser, Andrew G ^a   Bryant, Henry U ^a   Cohen, Ilene R ^a   Dally, Robert D ^a   Fong, Kin Chiu ^b   Frank, Scott A ^a   Hinklin, Ronald ^b   Jones, Scott A ^a   Lewis, George ^b   McCann, Denis J ^a   Rudmann, Daniel G ^a   Shepherd, Timothy A ^a   Tian, Hongqi ^b   Wallace, Owen B ^a   Wang, Minmin ^a   Wang, Yong ^a   Dodge, Jeffrey A ^a  

^a ELI LILLY AND COMPANY   (United States)

^b ARRAY BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; LY 2066948; LY 326315; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; NONHUMAN; OVARY; RAT; TISSUE SPECIFICITY; UTERUS; UTERUS MYOMA;

ANIMALS; BINDING SITES; BIOLOGICAL AVAILABILITY; CELL LINE; CELL PROLIFERATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; LEIOMYOMA; MAMMARY GLANDS, ANIMAL; MODELS, MOLECULAR; NAPHTHALENES; ORGAN SIZE; OVARY; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STRUCTURE-ACTIVITY RELATIONSHIP; UTERINE NEOPLASMS; UTERUS;

EID: 27444447023     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050723z     Document Type: Article

References (17)

1. Stewart, E. A. Uterine fibroids. Lancet 2001, 357, 293-298.
2. Cramer, S. F.; Patel, A. The frequency of uterine leiomyomas. Am. J. Clin. Pathol. 1990, 94, 435-438.
3. Buttram, V. C., Jr.; Reuter, R. C. Uterine leiomyomata: etiology, symptomatology, and management. Fertil. Steril. 1981, 36, 433-445.
4. Lethaby, A.; Vollenhoven, B.; Sowter, M. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review. Br. J. Obstet. Gynecol. 2002, 109, 1097-1108.
5. Lumsden, M. A.; West, C. P.; Baird, D. T. Tamoxifen prolongs luteal phase in premenopausal women but has no effect on the size of uterine fibroids. Clin. Endocrinol. 1989, 31, 335-343.
6. Sadan, O.; Ginath, S.; Sofer, D.; Rotmensch, S.; Debby, A.; Glezerman, M.; Zakut, H. The role of tamoxifen in the treatment of symptomatic uterine leiomyomata. A pilot study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2001, 96, 183-186.
7. Huppert, L. C. Induction of ovulation with clomiphene citrate. Fertil. Steril. 1979, 31, 1-8.
8. Palomba, S.; Sammartino, A.; Di Carlo, C.; Affinito, P.; Zullo, F.; Nappi, C. Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. Fertil. Steril. 2001, 76, 38-43.
9. Palomba, S.; Orio, F.; Morelli, M.; Russo, T.; Pellicano, M.; Zupi, E.; Lombardi, G.; Nappi, C.; Panici, P. L. B.; Zullo, F. Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study. J. Clin. Endocrinol. Metab. 2002, 87, 3603-3608.
10. Plouffe, L.; Siddhanti, S. The effect of selective estrogen receptor modulators on parameters of the hypothalamic-pituitary-gonadal axis. Ann. N. Y. Acad. Sci. 2001, 949, 251-158.
11. Dodge, J. A.; Ellis, K. K.; Hay, L. A.; Koenig, T. M.; Lugar, C.; Strouse, E. E.; Mitchell, D. Practical convergent synthesis of SERM 2. ACS Symp. Ser. 2002, 817, 133-140.
12. Walker, C. L.; Burroughs, K.; Davis, B.; Sowell, K.; Everitt, J.; Fuchs-Young, R. Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma. J. Soc. Gynecol. Invest. 2000, 7, 249-256.
13. Grese, T. A.; Cho, S.; Finley, D.; Godfrey, A. G.; Jones, C. D.; Lugar, C. W.; Martin, M. J.; Matsumoto, K.; Pennington, L. D.; Winter, M. W.; Adrian, M. D.; Cole, H. W.; Magee, D. E.; Phillips, D. L.; Rowley, E. R.; Short, L. L.; Glasebrook, A. L.; Bryant, H. U. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. J. Med. Chem. 1997, 40, 146-167.
14. Kelder, J.; Grootenhuis, P. D. J.; Bayada, D. M.; Delbressine, L. P. C.; Ploemen, J.-P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. 1999, 16, 1514-1519.
15. Palkowitz, A. D.; Glasebrook, A. L.; Thrasher, K. J.; Hauser, K. L.; Short, L. L.; Phillips, D. L.; Muehl, B. S.; Sato, M.; Shetler, P. K.; Cullinan, G. J.; Pell, T. R.; Bryant, H. U. Discovery and synthesis of [6-hydroxy-3[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]benzo[b] thiophene: a novel, highly potent, selective estrogen receptor modulator. J. Med. Chem. 1997, 40, 1407-1416.
16. Lyttle, C. R.; DeSombre, E. R. Uterine peroxidase as a marker for estrogen action. Proc. Natl. Acad. Sci. U.S.A. 1977, 74, 3162-3166.
17. Geiser, A. G.; Hummel, C. W.; Draper, M. W.; Henck, J. W. Cohen, I. R.; Rudmann, D. G.; Donnelly, K. B.; Adrian, M. D.; Shepherd, T. A.; Wallace, O. B.; McCann, D. J.; Oldham, S. W.; Bryant, H. U.; Sato, M.; Dodge, J. A. A new selective estrogen receptor modulator (SERM) with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulation Endocrinology 2005, 10.1210/en2005-0024. See http://endo.endojournals.org for manuscript in Rapid Electronic Publication format.